AI assistant
Sending…
Corvus Pharmaceuticals, Inc. — Director's Dealing 2024
May 7, 2024
32755_dirs_2024-05-07_8a916031-a728-4738-9535-6eb14f30da32.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2024-05-06
Reporting Person: Jones William Benton (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-06 | Common Stock | P | 20000 | $1.7312 | Acquired | 153773 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-06 | Warrant (Right to Buy) | $3.5 | P | 19357 | Acquired | 2025-06-30 | Common Stock (19357) | Direct |
Footnotes
F1: Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312.
More from Corvus Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Major Shareholding Notification
2026
Feb 5
Major Shareholding Notification
2026
Jan 30
Director's Dealing
2026
Jan 30
Major Shareholding Notification
2026
Jan 27
Capital/Financing Update
2026
Jan 23
Capital/Financing Update
2026
Jan 23
Capital/Financing Update
2026
Jan 20